Cargando…

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally

Hand, foot and mouth disease is a common acute viral infectious disease that poses a serious threat to the life and health of young children. With the development of an effective inactivated EV71 vaccine, CA16 has become the main pathogen causing HFMD. Effective and safe vaccines against this diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yun, Jiang, Qinfang, Huo, Xinqian, Yu, Li, Yang, Jinling, Zhao, Heng, Li, Dandan, Xu, Xingli, Jiang, Guorun, Zhang, Caixing, Li, Cong, Li, Yun, Zhang, Ying, Shao, Mingxiang, Liu, Baofeng, Shen, Lianzhong, Fan, Shengtao, Li, Qihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208166/
https://www.ncbi.nlm.nih.gov/pubmed/37217189
http://dx.doi.org/10.1080/21645515.2023.2209472
_version_ 1785046614113517568
author Liao, Yun
Jiang, Qinfang
Huo, Xinqian
Yu, Li
Yang, Jinling
Zhao, Heng
Li, Dandan
Xu, Xingli
Jiang, Guorun
Zhang, Caixing
Li, Cong
Li, Yun
Zhang, Ying
Shao, Mingxiang
Liu, Baofeng
Shen, Lianzhong
Fan, Shengtao
Li, Qihan
author_facet Liao, Yun
Jiang, Qinfang
Huo, Xinqian
Yu, Li
Yang, Jinling
Zhao, Heng
Li, Dandan
Xu, Xingli
Jiang, Guorun
Zhang, Caixing
Li, Cong
Li, Yun
Zhang, Ying
Shao, Mingxiang
Liu, Baofeng
Shen, Lianzhong
Fan, Shengtao
Li, Qihan
author_sort Liao, Yun
collection PubMed
description Hand, foot and mouth disease is a common acute viral infectious disease that poses a serious threat to the life and health of young children. With the development of an effective inactivated EV71 vaccine, CA16 has become the main pathogen causing HFMD. Effective and safe vaccines against this disease are urgently needed. In our previous study, a bivalent inactivated vaccine was shown to have good immunogenicity and to induce neutralizing antibodies in mice and monkeys. Repeated administration toxicity is a critical safety test in the preclinical evaluation of vaccines. In this study, BALB/c mice were used to evaluate the toxicity of the bivalent vaccine after multiple intradermal administrations. Clinical observation was performed daily, and body weight, food intake, hematological characteristics, serum biochemical parameters, antinuclear antibodies, CD4(+)/CD8a(+) T-cell proportions, bone marrow smear results and pathology results were recorded. The results showed that there was no significant change at the injection site and no adverse reactions related to the vaccine. The bivalent inactivated EV71-CA16 vaccine exhibits good safety in mice, and these results provide a sufficient basis for further clinical trials.
format Online
Article
Text
id pubmed-10208166
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102081662023-05-25 Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally Liao, Yun Jiang, Qinfang Huo, Xinqian Yu, Li Yang, Jinling Zhao, Heng Li, Dandan Xu, Xingli Jiang, Guorun Zhang, Caixing Li, Cong Li, Yun Zhang, Ying Shao, Mingxiang Liu, Baofeng Shen, Lianzhong Fan, Shengtao Li, Qihan Hum Vaccin Immunother Novel Vaccines Hand, foot and mouth disease is a common acute viral infectious disease that poses a serious threat to the life and health of young children. With the development of an effective inactivated EV71 vaccine, CA16 has become the main pathogen causing HFMD. Effective and safe vaccines against this disease are urgently needed. In our previous study, a bivalent inactivated vaccine was shown to have good immunogenicity and to induce neutralizing antibodies in mice and monkeys. Repeated administration toxicity is a critical safety test in the preclinical evaluation of vaccines. In this study, BALB/c mice were used to evaluate the toxicity of the bivalent vaccine after multiple intradermal administrations. Clinical observation was performed daily, and body weight, food intake, hematological characteristics, serum biochemical parameters, antinuclear antibodies, CD4(+)/CD8a(+) T-cell proportions, bone marrow smear results and pathology results were recorded. The results showed that there was no significant change at the injection site and no adverse reactions related to the vaccine. The bivalent inactivated EV71-CA16 vaccine exhibits good safety in mice, and these results provide a sufficient basis for further clinical trials. Taylor & Francis 2023-05-22 /pmc/articles/PMC10208166/ /pubmed/37217189 http://dx.doi.org/10.1080/21645515.2023.2209472 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Novel Vaccines
Liao, Yun
Jiang, Qinfang
Huo, Xinqian
Yu, Li
Yang, Jinling
Zhao, Heng
Li, Dandan
Xu, Xingli
Jiang, Guorun
Zhang, Caixing
Li, Cong
Li, Yun
Zhang, Ying
Shao, Mingxiang
Liu, Baofeng
Shen, Lianzhong
Fan, Shengtao
Li, Qihan
Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
title Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
title_full Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
title_fullStr Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
title_full_unstemmed Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
title_short Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
title_sort preclinical safety evaluation of a bivalent inactivated ev71-ca16 vaccine in mice immunized intradermally
topic Novel Vaccines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208166/
https://www.ncbi.nlm.nih.gov/pubmed/37217189
http://dx.doi.org/10.1080/21645515.2023.2209472
work_keys_str_mv AT liaoyun preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT jiangqinfang preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT huoxinqian preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT yuli preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT yangjinling preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT zhaoheng preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT lidandan preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT xuxingli preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT jiangguorun preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT zhangcaixing preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT licong preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT liyun preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT zhangying preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT shaomingxiang preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT liubaofeng preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT shenlianzhong preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT fanshengtao preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally
AT liqihan preclinicalsafetyevaluationofabivalentinactivatedev71ca16vaccineinmiceimmunizedintradermally